Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 3/2010

01.12.2010 | Case Report

Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?

verfasst von: Giacomo Biasucci, Piera Manfredi

Erschienen in: Journal of Inherited Metabolic Disease | Sonderheft 3/2010

Einloggen, um Zugang zu erhalten

Abstract

A 5-year-old girl was referred to the Department of Pediatrics and Neonatology, Guglielmo da Saliceto Hospital, Italy, because of growth retardation. Clinical and laboratory investigations showed pallor, hepatosplenomegaly, anemia and low/normal platelet count. Further investigations led to the diagnosis of Gaucher disease (GD). We believe this is the first report of growth hormone deficiency in a growth-retarded child with GD. After 1 year of imiglucerase replacement enzyme therapy, her bone age had normalized, linear growth rate had accelerated, and insulin growth factor-1 (IGF-1) and, perhaps more interestingly, growth hormone deficiency, had normalized. While the pathophysiological mechanisms underlying compromised growth in GD are poorly understood, the response to imiglucerase reported in this patient suggests that growth hormone deficiency is related to the underlying metabolic disorder in GD, rather than a primary endocrine pathology. Growth hormone deficiency adds to an already extensive list of possible clinical manifestations of this heterogeneous and complex disorder.
Literatur
Zurück zum Zitat Andersson H, Kaplan P, Kacena K et al (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122:1182–1190PubMedCrossRef Andersson H, Kaplan P, Kacena K et al (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122:1182–1190PubMedCrossRef
Zurück zum Zitat Barton DJ, Ludman MD, Benkov K et al (1989) Resting energy expenditure in Gaucher’s disease type 1: effect of Gaucher’s cell burden on energy requirements. Metabolism 38:1238–1243PubMedCrossRef Barton DJ, Ludman MD, Benkov K et al (1989) Resting energy expenditure in Gaucher’s disease type 1: effect of Gaucher’s cell burden on energy requirements. Metabolism 38:1238–1243PubMedCrossRef
Zurück zum Zitat Dweck A, Abrahamov A, Hadas-Halpern I et al (2002) Type I Gaucher disease in children with and without enzyme therapy. Pediatr Hematol Oncol 19:389–397PubMedCrossRef Dweck A, Abrahamov A, Hadas-Halpern I et al (2002) Type I Gaucher disease in children with and without enzyme therapy. Pediatr Hematol Oncol 19:389–397PubMedCrossRef
Zurück zum Zitat Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201–212PubMedCrossRef Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201–212PubMedCrossRef
Zurück zum Zitat Kaplan P, Andersson HC, Kacena KA et al (2006) The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 160:603–608PubMedCrossRef Kaplan P, Andersson HC, Kacena KA et al (2006) The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 160:603–608PubMedCrossRef
Zurück zum Zitat Kaplan P, Mazur A, Manor O et al (1996) Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129:149–153PubMedCrossRef Kaplan P, Mazur A, Manor O et al (1996) Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129:149–153PubMedCrossRef
Zurück zum Zitat Kauli R, Zaizov R, Lazar L et al (2000) Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2:158–163PubMed Kauli R, Zaizov R, Lazar L et al (2000) Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2:158–163PubMed
Zurück zum Zitat Langeveld M, Endert E, Wiersinga WM et al (2007) Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. J Inherit Metab Dis 30:985PubMedCrossRef Langeveld M, Endert E, Wiersinga WM et al (2007) Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. J Inherit Metab Dis 30:985PubMedCrossRef
Zurück zum Zitat Pastores GM, Weinreb NJ, Aerts H et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4 Suppl 5):4–14PubMedCrossRef Pastores GM, Weinreb NJ, Aerts H et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4 Suppl 5):4–14PubMedCrossRef
Zurück zum Zitat Rite S, Baldellou A, Giraldo P et al (2002) Insulin-like growth factors in childhood-onset Gaucher disease. Pediatr Res 52:109–112PubMedCrossRef Rite S, Baldellou A, Giraldo P et al (2002) Insulin-like growth factors in childhood-onset Gaucher disease. Pediatr Res 52:109–112PubMedCrossRef
Zurück zum Zitat Ross RJ, Buchanan CR (1990) Growth hormone secretion: its regulation and the influence of nutritional factors. Nutr Res Rev 3:143–162PubMedCrossRef Ross RJ, Buchanan CR (1990) Growth hormone secretion: its regulation and the influence of nutritional factors. Nutr Res Rev 3:143–162PubMedCrossRef
Zurück zum Zitat Tanner J, Whitehouse R (1976) Clinical longitudinal standards for height, weight, height velocity and weight velocity and stages of puberty. Arch Dis Child 51:170–179PubMedCrossRef Tanner J, Whitehouse R (1976) Clinical longitudinal standards for height, weight, height velocity and weight velocity and stages of puberty. Arch Dis Child 51:170–179PubMedCrossRef
Zurück zum Zitat Vitery FE (1981) Primary protein-energy malnutrition: clinical, biochemical and metabolic changes. In: Suskind RM (ed) Textbook of pediatric nutrition. Raven Press, New York, pp 189–215 Vitery FE (1981) Primary protein-energy malnutrition: clinical, biochemical and metabolic changes. In: Suskind RM (ed) Textbook of pediatric nutrition. Raven Press, New York, pp 189–215
Zurück zum Zitat Weinreb NJ, Aggio MC, Andersson HC et al (2004) Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 41(4 Suppl 5):15–22PubMedCrossRef Weinreb NJ, Aggio MC, Andersson HC et al (2004) Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 41(4 Suppl 5):15–22PubMedCrossRef
Zurück zum Zitat Weinreb NJ, Charrow J, Andersson HC et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 13:112–119CrossRef Weinreb NJ, Charrow J, Andersson HC et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 13:112–119CrossRef
Zurück zum Zitat Zevin S, Abrahamov A, Hadas-Halpern I et al (1993) Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med 86:565–573PubMed Zevin S, Abrahamov A, Hadas-Halpern I et al (1993) Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med 86:565–573PubMed
Zurück zum Zitat Zimran A, Abrahamov A, Elstein D (2000) Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr Med Assoc J 2:80–81PubMed Zimran A, Abrahamov A, Elstein D (2000) Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr Med Assoc J 2:80–81PubMed
Metadaten
Titel
Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?
verfasst von
Giacomo Biasucci
Piera Manfredi
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe Sonderheft 3/2010
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-009-9016-7

Weitere Artikel der Sonderheft 3/2010

Journal of Inherited Metabolic Disease 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.